文献速递认知障碍与痴呆

多奈单抗治疗后淀粉样蛋白减少与tau病理及临床结局的关联:TRAILBLAZER-ALZ随机临床试验

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

TRAILBLAZER-ALZ是一项2期安慰剂对照随机试验的事后分析,纳入272例早期症状性阿尔茨海默病患者,评估多奈单抗治疗后淀粉样蛋白减少与tau病理及临床指标的关系。结果显示基线淀粉样蛋白水平与淀粉样蛋白减少幅度直接相关,与完全清除概率呈负相关;多奈单抗以区域依赖方式减缓tau积累,仅在APOE ε4携带者中淀粉样蛋白减少百分比与iADRS变化显著相关。

要点

  • 多奈单抗诱导的24周淀粉样蛋白减少速率与基线淀粉样蛋白量中度相关(r=-0.54)。
  • 模型提示停药后淀粉样蛋白需3.9年(95%预测区间1.9-8.3年)才重新累积至24.1-centiloid阈值。
  • 仅在APOE ε4携带者中,淀粉样蛋白减少百分比与iADRS变化显著相关(95%CI 24%-59%)。

核心结论

  • 事后分析提示,多奈单抗治疗者基线淀粉样蛋白水平与淀粉样蛋白减少幅度直接相关,与实现完全淀粉样蛋白清除的概率呈负相关。
  • 多奈单抗诱导的tau减缓在完全淀粉样蛋白清除者及病理序列中较晚受累脑区更明显。
  • 作者认为其他试验数据对证实上述观察很重要,尤其是按APOE ε4状态划分的治疗反应。

研究设计与样本

  • TRAILBLAZER-ALZ为2期、安慰剂对照、随机临床试验,2017年12月18日至2020年12月4日在美国和加拿大的56个中心开展。
  • 双盲期最长76周,随后48周随访期;纳入60至85岁、记忆功能渐变进展6个月以上、早期症状性阿尔茨海默病、淀粉样蛋白升高且tau水平中等的参与者。
  • 多奈单抗每4周给药:前3次700 mg,之后1400 mg最长至72周;第24周和第52周根据淀粉样蛋白清除情况进行盲法减量评估。
  • 主要研究随机272例参与者(平均[SD]年龄75.2[5.5]岁;145例女性[53.3%]);筛查1955例中排除1683例。

主要发现

  • 多奈单抗诱导的24周淀粉样蛋白减少速率与基线淀粉样蛋白量中度相关(Spearman相关系数r=-0.54;95%CI -0.66至-0.39;P<.001)。
  • 模型提出假设:停用多奈单抗后,淀粉样蛋白需3.9年(95%预测区间1.9-8.3年)才重新累积至24.1-centiloid阈值。
  • 使用新皮质和区域标准化摄取值比(以小脑灰质为参考区)测量,多奈单抗以区域依赖方式减缓tau积累。
  • 疾病进展模型发现,淀粉样蛋白减少百分比与整合阿尔茨海默病评定量表(iADRS)变化之间的显著关联仅见于载脂蛋白E(APOE)ε4携带者(95%CI 24%-59%;P<.001)。

关键数值与推荐

  • 24周淀粉样蛋白减少速率与基线淀粉样蛋白量的Spearman相关系数r=-0.54(95%CI -0.66至-0.39;P<.001)。
  • 停药后淀粉样蛋白重新累积至24.1-centiloid阈值的模型预测时间为3.9年(95%预测区间1.9-8.3年)。
  • 仅在APOE ε4携带者中,淀粉样蛋白减少百分比与iADRS变化显著相关(95%CI 24%-59%;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为事后分析(post hoc analyses)。
  • 作者指出其他试验数据对证实上述观察很重要,尤其是按APOE ε4状态划分的治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease. OBJECTIVE: To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology and clinical measures. DESIGN, SETTING, AND PARTICIPANTS: The Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) was a phase 2, placebo-controlled, randomized clinical trial conducted from December 18, 2017, to December 4, 2020, with a double-blind period of up to 76 weeks and a 48-week follow-up period. The study was conducted at 56 centers in the US and Canada. Enrolled were participants from 60 to 85 years of age with gradual and progressive change in memory function for 6 months or more, early symptomatic Alzheimer disease, elevated amyloid, and intermediate tau levels. INTERVENTIONS: Donanemab (an antibody specific for the N-terminal pyroglutamate β-amyloid epitope) dosing was every 4 weeks: 700 mg for the first 3 doses, then 1400 mg for up to 72 weeks. Blinded dose-reduction evaluations occurred at 24 and 52 weeks based on amyloid clearance. MAIN OUTCOMES AND MEASURES: Change in amyloid, tau, and clinical decline after donanemab treatment. RESULTS: The primary study randomized 272 participants (mean [SD] age, 75.2 [5.5] years; 145 female participants [53.3%]). The trial excluded 1683 of 1955 individuals screened. The rate of donanemab-induced amyloid reduction at 24 weeks was moderately correlated with the amount of baseline amyloid (Spearman correlation coefficient r, -0.54; 95% CI, -0.66 to -0.39; P < .001). Modeling provides a hypothesis that amyloid would not reaccumulate to the 24.1-centiloid threshold for 3.9 years (95% prediction interval, 1.9-8.3 years) after discontinuing donanemab treatment. Donanemab slowed tau accumulation in a region-dependent manner as measured using neocortical and regional standardized uptake value ratios with cerebellar gray reference region. A disease-progression model found a significant association between percentage amyloid reduction and change on the integrated Alzheimer Disease Rating Scale only in apolipoprotein E (APOE) ε4 carriers (95% CI, 24%-59%; P < .001). CONCLUSIONS AND RELEVANCE: Results of post hoc analyses for donanemab-treated participants suggest that baseline amyloid levels were directly associated with the magnitude of amyloid reduction and inversely associated with the probability of achieving complete amyloid clearance. The donanemab-induced slowing of tau was more pronounced in those with complete amyloid clearance and in brain regions identified later in the pathologic sequence. Data from other trials will be important to confirm aforementioned observations, particularly treatment response by APOE ε4 status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367403.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Shcherbinin S, Evans CD, Lu M, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36094645. doi:10.1001/jamaneurol.2022.2793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。